Zydus Cadila gets USFDA nod for anti-infections tablets

Drug firm Zydus Cadila has received final approval from the US health regulator to market its Metronidazole tablets used for the treatment of infections caused by bacteria or parasites.
The company has received "final approval from the United States Food and Drug Administration (USFDA) to market Metronidazole tablets USP in strengths of 250 mg and 500 mg," Cadila Healthcare, the listed entity of the Zydus Group, said in a BSE filing.
The drug will be produced at the group's formulations manufacturing facility at Baddi, it added.
"The group now has more than 105 approvals and has so far filed nearly 275 abbreviated new drug applications (ANDAs) since the commencement of the filing process in FY 2003-04," Cadila Healthcare said.

Shares of the company were trading 1.85 per cent lower at Rs 366.50 apiece in the afternoon trade on BSE.